SAN FRANCISCO, CA USA ( - Dr. Marc Smaldone presented an overview of the role and reliability of renal mass biopsy given the heterogeneity of renal tumors.

Historically there were concerns about sampling error, low negative predictive value, technical failure, procedure-related complications, and biopsy tract seeding. However, modern renal mass biopsy is safe, and accuracy rates greater than 90%, with sensitivities and specificities ranging from 80-92% and 83-100%, respectively, having been reported. The use of renal mass biopsy has increased in the modern era, primarily to identify patients who harbor benign lesions and for whom treatment may be avoided, such as the frail and elderly. 

gucancerssympalt thumbFalse negative biopsy rates in contemporary series are < 5%, and repeat biopsy in non-diagnostic cases has accuracy rates > 80%. Tumor tract seeding, long a feared complication of renal mass biopsy, has a reported incidence of < 0.01%. The largest modern clinical limitation of renal mass biopsy is the inability to differentiate low- from high-risk malignancy by tumor grade. Using core biopsy rather than fine needle aspiration has improved accuracy of renal mass biopsy.

The ability of renal mass biopsy to predict tumor phenotype is uncertain, and recent data illustrate that genomic analyses underestimate the mutational burden of heterogeneous tumors. Improvement in the ability of renal mass biopsy to accurately predict tumor phenotype could impact development of personalized treatment strategies for kidney cancer. As renal mass biopsy has improved, the role of biopsy to help guide individualized therapy has become more clearly defined. In the future, molecular information from renal mass biopsy specimens will be integrated into clinical algorithms to guide patient counseling and inform personalized decision-making.

Highlights of a presentation by Marc C. Smaldone, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

The Fox Chase Cancer Center, Philadelphia, PA USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for

View Full 2014 GU Cancers Symposium Coverage



Upcoming urology industry events
April 27-29, 2018 / European Society for Medical Oncology Update for Practising Oncologists
European Society for Medical Oncology Update for Practising Oncologists
May 14, 2018 / InterContinental Mark Hopkins Hotel
SITC Cancer Immune Responsiveness Workshop
May 16-17, 2018 / InterContinental Mark Hopkins Hotel
SITC Immuno-Oncology Biomarkers: State of the Art Workshop
May 17, 2018 / Moscone Convention Center North/South, San Francisco, CA
SAU 2018 Annual Meeting at the AUA
Print publications focusing on urological cancer treatments through original commentary & articles

Everyday Urology™ - Oncology Insights

From the Editor

Prostate Cancer and Prostatic Diseases

From the Editor